(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Dr. Redlener Applauds Historic Effort but Points out Potential Risk if America,s Safety Net Programs Are Lost in Final Health Care Reform ,, NEW YORK, Dec. 4 The New England Journal of Medicine
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Are angry women more like men? 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2...tudies on the use of stem cells for cardiac repair...ing of the Heart Failure Association of the Europe...mish-Partenkirchen, Germany. Findings in experime...Over one hundred top cardiologists from all over E...
... walk a few days a week cut death risk in half, st...y News) -- Even a moderate amount of exercise can...n middle-aged and elderly American veterans reveal...ays a week was enough to halve the risk of prematu...
...arnings teleconference today at 10:00 a.m. EST by ...01417, or listen on the Web at: http://www.ai...s.htm ., LEHIGH VALLEY, Pa., Jan. 23 Air Product...1,2007. Net income increased 15 percent, and dilut...
...l,s Success at European Patent Hearing is Confirme... EDINBURGH, Scotland, January 23 The European Pa...tent (the ,131, patent) not,valid as granted. In a...announcing the EPO ruling as a success, despite th...
...t Be Offered Advanced Therapy, HOLLYWOOD, Fla., J...ke treatment using clot-busting drugs may succeed ...ts directly in the brain, according,to data being ...IV),stroke therapy aren,t given the chance to succ...
.... 22 Today,s USA Today,features a major story in ...new book telling the stories of more than 40 organ...holas Green, who was a 7-year-old boy killed,durin...onors., However, nearly 100,000 Americans are cur...
Other Medicine News:Health News:A Little Regular Exercise Extends Men's Lives 2Health News:A Little Regular Exercise Extends Men's Lives 3Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 2Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 3Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 4Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 5Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 6Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 7Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 8Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 9Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 10Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 11Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 12Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 13Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 14Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 15Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 16Health News:Aircraft Medical: European Patent Hearing 2Health News:Stroke Undertreated 2Health News:Stroke Undertreated 3(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Allen Medical Systems Announces Surgeon Spotlight Series Interview 5143 1Allen Medical Systems Announces Surgeon Spotlight Series Interview 5143 2Allen Medical Systems Announces Surgeon Spotlight Series Interview 5143 3Saint Josephs Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion 5141 1Saint Josephs Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion 5141 2Saint Josephs Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion 5141 3Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 5139 1Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 5139 2... Nastech Pharmaceutical,Company Inc. (Nasdaq: NS...al,trial evaluating the Company,s PYY3-36 Nasal Sp...ximately 500 obese patients for a six-month,random...eight loss as the,primary endpoint. The Phase 2 s...,Nastech,s PYY3-36 Nasal Spray compared to placebo...
.... 1 Sanofi-aventis,announced that the U.S. Food a...(R) (docetaxel) Injection Concentrate in combinati... therapy of locally advanced squamous cell,carcino...dergo,chemoradiotherapy and surgery. The FDA base...domized,open-label, international trial, TAX 324, ...
Other Medicine Technology:Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity 2Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity 3Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 2Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 3Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 4Woodlyn Refractor
Illuminated Phoroptor
Ultramatic RX Master PHOROPTOR Refracting Instrument - Minus Cylinder Black
Red Lens Maddox
Medicine Products: